Literature DB >> 24694365

Inhibitor binding to Hsp90: a review of thermodynamic, kinetic, enzymatic, and cellular assays.

Vilma Petrikaite, Daumantas Matulis1.   

Abstract

This manuscript reviews published Hsp90 inhibitors and Hsp90-binding compounds. The main goal of the article is to overview the structures of existing Hsp90 inhibitors and to draw correlations between compound structure and binding affinity. Furthermore, it is important to emphasize all thermodynamic binding data especially the data that includes the enthalpies, entropies, heat capacities, and the volumes of binding. This information is important for the goal of drawing the principles of a more rational drug design. The distinction between the observed and the intrinsic binding parameters should also be emphasized. Out of nearly 280 compounds surveyed, most could be classified to three chemical groups (resorcinol-bearing, geldanamycin derivatives, and purine-pyrimidine derivatives) and only few of them have determined intrinsic thermodynamic parameters other than the dissociation/inhibition constant. Since most compounds are being developed as anticancer agents, the available cell growth inhibition data is also included. Possible limitations of the use of enzymatic inhibition and the cancer cell growth inhibition data is discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24694365     DOI: 10.2174/1389203715666140331115032

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  2 in total

1.  A docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania Hsp90.

Authors:  Luana Carneiro Palma; Luiz Felipe Gomes Rebello Ferreira; Antonio Luis de Oliveira Almeida Petersen; Beatriz Rocha Simões Dias; Juliana Perrone Bezerra de Menezes; Diogo Rodrigo de Magalhães Moreira; Marcelo Zaldini Hernandes; Patricia Sampaio Tavares Veras
Journal:  Sci Rep       Date:  2019-10-14       Impact factor: 4.379

2.  Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.

Authors:  Simonas Daunys; Daumantas Matulis; Vilma Petrikaitė
Journal:  Sci Rep       Date:  2019-11-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.